Search

Your search keyword '"Schreiner, Jochen"' showing total 45 results
Start Over Author "Schreiner, Jochen"
45 results on '"Schreiner, Jochen"'

1. Characterization of a $^{220}$Rn source for low-energy electronic recoil calibration of the XENONnT detector

Author

Jörg, Florian, Li, Shengchao, Schreiner, Jochen, Simgen, Hardy, and Lang, Rafael F.

Subjects
Physics - Instrumentation and Detectors, Astrophysics - Instrumentation and Methods for Astrophysics, Nuclear Experiment
Abstract

Low-background liquid xenon detectors are utilized in the investigation of rare events, including dark matter and neutrinoless double beta decay. For their calibration, gaseous $^{220}$Rn can be used. After being introduced into the xenon, its progeny isotope $^{212}$Pb induces homogeneously distributed, low-energy ($<30$ keV) electronic recoil interactions. We report on the characterization of such a source for use in the XENONnT experiment. It consists of four commercially available $^{228}$Th sources with an activity of 55 kBq. These sources provide a high $^{220}$Rn emanation rate of about 8 kBq. We find no indication for the release of the long-lived $^{228}$Th above 1.7 mBq. Though an unexpected $^{222}$Rn emanation rate of about 3.6 mBq is observed, this source is still in line with the requirements for the XENONnT experiment., Comment: 9 pages, 5 figures

Published
2023
Full Text
View/download PDF

2. Modeling of GERDA Phase II data

Author

GERDA collaboration, Agostini, Matteo, Bakalyarov, Alexander M., Balata, Marco, Barabanov, Igor, Baudis, Laura, Bauer, Christian, Bellotti, Enrico, Belogurov, Sergej, Bettini, Alessandro, Bezrukov, Leonid, Borowicz, Dariusz, Bossio, Elisabetta, Bothe, Vikas, Brudanin, Victor, Brugnera, Riccardo, Caldwell, Allen, Cattadori, Carla, Chernogorov, Andrey, Comellato, Tommaso, D'Andrea, Valerio, Demidova, Elena V., Di Marco, Natalia, Domula, Alexander, Doroshkevich, Evgenyi, Egorov, Viacheslav, Fischer, Felix, Fomina, Maria, Gangapshev, Albert, Garfagnini, Alberto, Gooch, Chris, Grabmayr, Peter, Gurentsov, Valery, Gusev, Konstantin, Hakenmüller, Janina, Hemmer, Sabine, Hiller, Roman, Hofmann, Werner, Hult, Mikael, Inzhechik, Lev V., Csáthy, Jozsef Janicskó, Jochum, Josef, Junker, Matthias, Kazalov, Vladimir, Kermaïdic, Yoann, Kihm, Thomas, Kirpichnikov, Igor V., Klimenko, Alexander, Kneißl, Raphael, Knöpfle, Karl T., Kochetov, Oleg, Kornoukhov, Vasily N., Krause, Patrick, Kuzminov, Valery V., Laubenstein, Matthias, Lazzaro, Andrea, Lindner, Manfred, Lippi, Ivano, Lubashevskiy, Alexey, Lubsandorzhiev, Bayarto, Lutter, Guillaume, Macolino, Carla, Majorovits, Bela, Maneschg, Werner, Miloradovic, Michael, Mingazheva, Rizalina, Misiaszek, Marcin, Moseev, Pavel, Nemchenok, Igor, Panas, Krysztof, Pandola, Luciano, Pelczar, Krysztof, Pertoldi, Luigi, Piseri, Paolo, Pullia, Alberto, Ransom, Chloe, Riboldi, Stefano, Rumyantseva, Nadezda, Sada, Cinzia, Salamida, Francesco, Schönert, Stefan, Schreiner, Jochen, Schütt, Mario, Schütz, Ann-Katrin, Schulz, Oliver, Schwarz, Mario, Schwingenheuer, Bernhard, Selivanenko, Oleg, Shevchik, Egor, Shirchenko, Mark, Simgen, Hardy, Smolnikov, Anatoly, Stukov, Danila, Vanhoefer, Laura, Vasenko, Andrey A., Veresnikova, Anna, Vignoli, Chiara, von Sturm, Katharina, Wester, Thomas, Wiesinger, Christoph, Wojcik, Marcin, Yanovich, Evgeny, Zatschler, Birgit, Zhitnikov, Igor, Zhukov, Sergey V., Zinatulina, Daniya, Zschocke, Andreas, Zsigmond, Anna J., Zuber, Kai, and Zuzel, Grzegorz

Subjects
Nuclear Experiment, Physics - Instrumentation and Detectors
Abstract

The GERmanium Detector Array (GERDA) experiment at the Gran Sasso underground laboratory (LNGS) of INFN is searching for neutrinoless double-beta ($0\nu\beta\beta$) decay of $^{76}$Ge. The technological challenge of GERDA is to operate in a "background-free" regime in the region of interest (ROI) after analysis cuts for the full 100$\,$kg$\cdot$yr target exposure of the experiment. A careful modeling and decomposition of the full-range energy spectrum is essential to predict the shape and composition of events in the ROI around $Q_{\beta\beta}$ for the $0\nu\beta\beta$ search, to extract a precise measurement of the half-life of the double-beta decay mode with neutrinos ($2\nu\beta\beta$) and in order to identify the location of residual impurities. The latter will permit future experiments to build strategies in order to further lower the background and achieve even better sensitivities. In this article the background decomposition prior to analysis cuts is presented for GERDA Phase II. The background model fit yields a flat spectrum in the ROI with a background index (BI) of $16.04^{+0.78}_{-0.85} \cdot 10^{-3}\,$cts/(kg$\cdot$keV$\cdot$yr) for the enriched BEGe data set and $14.68^{+0.47}_{-0.52} \cdot 10^{-3}\,$cts/(kg$\cdot$keV$\cdot$yr) for the enriched coaxial data set. These values are similar to the one of Gerda Phase I despite a much larger number of detectors and hence radioactive hardware components.

Published
2019
Full Text
View/download PDF

4. Growth differentiation factor 15 (GDF-15) is induced by mitotane in adrenocortical carcinoma and associated with poor prognosis and impaired responsiveness to immunotherapy

Author

Weigand, Isabel, primary, Triebig, Alexandra, additional, Tanja, Maier, additional, Anderlik, Tanja, additional, Remde, Hanna, additional, Landwehr, Laura-Sophie, additional, Kimpel, Otilia, additional, Reuter, Miriam, additional, Schreiner, Jochen, additional, Wedekink, Florian, additional, Hoster, Eva, additional, Schwarzlmueller, Paul, additional, Reincke, Martin, additional, Wischhusen, Jorg, additional, Fassnacht, Martin, additional, and Matthias, Kroiss, additional

Published
2024
Full Text
View/download PDF

5. A Rn-220 source for the calibration of low-background experiments

Author

Lang, Rafael F., Brown, Andrew, Brown, Ethan, Cervantes, Mayra, Macmullin, Sean, Masson, Darryl, Schreiner, Jochen, and Simgen, Hardy

Subjects
Physics - Instrumentation and Detectors, Astrophysics - Instrumentation and Methods for Astrophysics
Abstract

We characterize two 40 kBq sources of electrodeposited Th-228 for use in low-background experiments. The sources efficiently emanate Rn-220, a noble gas that can diffuse in a detector volume. Rn-220 and its daughter isotopes produce alpha, beta, and gamma-radiation, which may used to calibrate a variety of detector responses and features, before decaying completely in only a few days. We perform various tests to place limits on the release of other long-lived isotopes. In particular, we find an emanation of <0.008 atoms/min/kBq (90% CL) for Th-228 and 1.53 atoms/min/kBq for Ra-224. The sources lend themselves in particular to the calibration of detectors employing liquid noble elements such as argon and xenon. With the source mounted in a noble gas system, we demonstrate that filters are highly efficient in reducing the activity of these longer-lived isotopes further. We thus confirm the suitability of these sources even for use in next-generation experiments, such as XENON1T/XENONnT, LZ, and nEXO., Comment: 15 pages, 9 figures

Published
2016
Full Text
View/download PDF

8. High-Dose Rate Brachytherapy Combined with PD-1 Blockade as a Treatment for Metastatic Adrenocortical Carcinoma – A Single Center Case Series.

Author

Schwarzlmueller, Paul, Corradini, Stefanie, Seidensticker, Max, Zimmermann, Petra, Schreiner, Jochen, Maier, Tanja, Triebig, Alexandra, Knösel, Thomas, Pazos, Montserrat, Pfluger, Thomas, Weigand, Isabel, Belka, Claus, Ricke, Jens, Reincke, Martin, Schmidmaier, Ralf, and Kroiss, Matthias

Subjects
HIGH dose rate brachytherapy, DRUG side effects, EXTERNAL beam radiotherapy, RADIOISOTOPE brachytherapy, CUSHING'S syndrome, IMMUNE checkpoint inhibitors
Abstract

The response rate of advanced adrenocortical carcinoma (ACC) to standard chemotherapy with mitotane and etoposide/doxorubicin/cisplatin (EDP-M) is unsatisfactory, and benefit is frequently short lived. Immune checkpoint inhibitors (CPI) have been examined in patient's refractory to EDP-M, but objective response rates are only approximately 15%. High-dose rate brachytherapy (HDR-BT) is a catheter-based internal radiotherapy and expected to favorably combine with immunotherapies. Here we describe three cases of patients with advanced ACC who were treated with HDR-BT and the CPI pembrolizumab. None of the tumors were positive for established response markers to CPI. All patients were female, had progressed on EDP-M and received external beam radiation therapy for metastatic ACC. Pembrolizumab was initiated 7 or 23 months after brachytherapy in two cases and prior to brachytherapy in one case. Best response of lesions treated with brachytherapy was complete (n=2) or partial response (n=1) that was ongoing at last follow up after 23, 45 and 4 months, respectively. Considering all sites of tumor, response was complete and partial remission in the two patients with brachytherapy prior to pembrolizumab. The third patient developed progressive disease with severe Cushing's syndrome and died due to COVID-19. Immune-related adverse events of colitis (grade 3), gastroduodenitis (grade 3), pneumonitis (grade 2) and thyroiditis (grade 1) occurred in the two patients with systemic response. HDR-BT controlled metastases locally. Sequential combination with CPI therapy may enhance an abscopal antitumoral effect in non-irradiated metastases in ACC. Systematic studies are required to confirm this preliminary experience and to understand underlying mechanisms. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

9. Low-grade inflammation during the glucocorticoid withdrawal phase in patients with Cushing's syndrome

Author

Vogel, Frederick, primary, Braun, Leah, additional, Zopp, Stephanie, additional, Nowak, Elisabeth, additional, Schreiner, Jochen, additional, Benz, Irina, additional, Rubinstein, German, additional, Künzel, Heike, additional, Ritzel, Katrin, additional, Kroiss, Matthias, additional, Honegger, Jürgen, additional, Beuschlein, Felix, additional, Schilbach, Katharina, additional, Teupser, Daniel, additional, Bidlingmaier, Martin, additional, and Reincke, Martin, additional

Published
2023
Full Text
View/download PDF

10. Low-grade inflammation during the glucocorticoid withdrawal phase in patients with Cushing's syndrome

Author

Vogel, Frederick; https://orcid.org/0000-0001-8821-8968, Braun, Leah; https://orcid.org/0000-0002-4963-5184, Zopp, Stephanie, Nowak, Elisabeth, Schreiner, Jochen, Benz, Irina, Rubinstein, German; https://orcid.org/0000-0002-7260-0748, Künzel, Heike, Ritzel, Katrin, Kroiss, Matthias, Honegger, Jürgen; https://orcid.org/0000-0002-7249-8077, Beuschlein, Felix; https://orcid.org/0000-0001-7826-3984, Schilbach, Katharina; https://orcid.org/0000-0002-8667-0296, Teupser, Daniel, Bidlingmaier, Martin; https://orcid.org/0000-0002-4681-6668, Reincke, Martin; https://orcid.org/0000-0002-9817-9875, Vogel, Frederick; https://orcid.org/0000-0001-8821-8968, Braun, Leah; https://orcid.org/0000-0002-4963-5184, Zopp, Stephanie, Nowak, Elisabeth, Schreiner, Jochen, Benz, Irina, Rubinstein, German; https://orcid.org/0000-0002-7260-0748, Künzel, Heike, Ritzel, Katrin, Kroiss, Matthias, Honegger, Jürgen; https://orcid.org/0000-0002-7249-8077, Beuschlein, Felix; https://orcid.org/0000-0001-7826-3984, Schilbach, Katharina; https://orcid.org/0000-0002-8667-0296, Teupser, Daniel, Bidlingmaier, Martin; https://orcid.org/0000-0002-4681-6668, and Reincke, Martin; https://orcid.org/0000-0002-9817-9875

Abstract

IMPORTANCE Endogenous Cushing's syndrome (CS) leads to profound immunosuppression. Successful surgery induces biochemical remission and reversal of immunosuppression, which is characterized by clinical signs of glucocorticoid withdrawal and associated with increased susceptibility to infections and thromboembolic complications. OBJECTIVE We hypothesized that the glucocorticoid withdrawal phase is characterized by low-grade inflammation that may be related to patient-relevant outcomes. SETTING In this retrospective observational study, we analyzed longitudinal data from 80 patients with CS prospectively enrolled in the German Cushing's registry between 2012 and 2021. All enrolled patients underwent successful surgery. In a second step, a case-control study was performed in 25 of the patients with age-, gender-, and body mass index-matched control patients in whom hypercortisolism was excluded. Analyses included the inflammatory markers C-reactive protein and interleukin-6, as well as body composition, muscle function testing, and quality-of-life questionnaires. The patients were studied during active CS and in the postoperative remission phase 1, 3, 6, 12, and 24 months after surgery. RESULTS Compared with the preoperative phase and matched controls, patients with CS had increased systemic inflammatory markers in the early remission phase. One month following surgery, median (interquartile range) C-reactive protein was 0.48 mg dL-1 (0.14-0.90) vs 0.10 mg dL-1 (0.06-0.39) during active CS (P ≤ .001). Similarly, interleukin-6 1 month after surgery was 7.2 pg mL-1 (3.3-11.7) vs 1.7 pg mL-1 (1.5-2.5) during active CS (P ≤ .001). Obesity and hemoglobin A1c (HbA1c) were associated with increased inflammation levels. This proinflammatory state lasted until 1 year following surgery. Moreover, inflammatory markers during early remission showed an inverse correlation with long-term muscle function. CONCLUSIONS The glucocorticoid withdrawal phase is associated with a low-grade

Published
2023

11. Establishment and characterization of a human adrenocortical cel line

Author

Schreiner, Jochen Josef

Subjects
Zelllinie, Zellkultur, ddc:610, 610 Medizin und Gesundheit, Nebennierenrindenkarzinom
Abstract

Background: The response of advanced adrenocortical carcinoma (ACC) to current chemotherapies is unsatisfactory and a limited rate of response to immunotherapy was observed in clinical trials. High tumour mutational burden (TMB) and the presence of a specific DNA signature are characteristic features of tumours with mutations in the gene MUTYH encoding the mutY DNA glycosylase. Both have been shown to potentially predict the response to immunotherapy. High TMB in an ACC cell line model has not been reported yet. Design and methods: The JIL-2266 cell line was established from a primary ACC tumour, comprehensively characterised and oxidative damage, caused by a dysfunctional mutY DNA glycosylase, confirmed. Results: Here, we characterise the novel patient-derived ACC cell line JIL-2266, which is deficient in mutY-dependent DNA repair. JIL-2266 cells have a consistent STR marker profile that confirmed congruousness with primary ACC tumour. Cells proliferate with a doubling time of 41 ± 13 h. Immunohistochemistry revealed positivity for steroidogenic factor-1. Mass spectrometry did not demonstrate significant steroid hormone synthesis. JIL-2266 have hemizygous mutations in the tumour suppressor gene TP53 (c.859G>T:p.E287X) and MUTYH (c.316C>T:p.R106W). Exome sequencing showed 683 single nucleotide variants and 4 insertions/deletions. We found increased oxidative DNA damage in the cell line and the corresponding primary tumour caused by impaired mutY DNA glycosylase function and accumulation of 8-oxoguanine. Conclusion: This model will be valuable as a pre-clinical ACC cell model with high TMB and a tool to study oxidative DNA damage in the adrenal gland., Hintergrund: Das Therapieansprechen von fortgeschrittenen Nebennierenrindenkarzinomen (ACC) unter den aktuellen Chemotherapieregimen ist nicht zufriedenstellend.Ebenfalls zeigte sich in klinischen Studien nur ein limitiertes Ansprechen auf Immuntherapien. Eine hohe Mutationslast (TMB) und das Vorhandensein einer spezifischen DNA Signatur sind charakteristisch für Tumore mit Mutationen in dem Gen MUTYH, welches die mutY-DNA-Glykosilase kodiert. Es wurde gezeigt, dass dies potentiell ein Ansprechen auf eine Immontherapie vorhersagen kann. Eine hohe Mutationslast in ein ACC Zellline konnte bis jetzt noch nicht gezeigt werden. Methoden: Die JIL--2266 Zelllinie wurde etabliert aus einem primären ACC-Tumor. Diese wurde umfänglich charakterisiert und oxidativer Schaden, welcher durch eine dysfunktionelle mutY DNA Glykosilase verursacht wird, konnte gezeigt werden. Ergebnis: Wir charakterisierten eine neue ACC Zelllinie JIL-2266, welche eine Defizienz in dem mutY DNA-Reperaturmechanismus aufweist. Die JIL-2266 Zellen weisen ein mit dem Primärtumor kongruentes STR-Profil auf. Die Zellen proliferieren mit einer Verdopplungszeit von 41 bis 13h. Die immunhisochemische Färbung zeigte eine Positivität für SF-1. In der Massenspektrometrie fand sich keine signifikante Steroidproduktion. Die JIL-2266 haben eine hemizygote Mutation in dem Tumorsuppressorgen TP53 und MUTYH. Exomsequenzierung zeigte 683 SNVs. Wir fanden erhöhten oxidativen DNA Schaden in der Zelllinie und im Primärtumor, verursacht durch eine gestörte mutY Glykosilase Funktion und eine Anhäufung von 8-Oxoguanin. Zusammenfassung: Dieses Zellinie ist ein wertvolles ACC Modell mit einer hohen Mutationslast und ein Werkzeug um oxidativen DNA Schaden in der Nebenniere zu untersuchen.

Published
2023
Full Text
View/download PDF

12. Outcome of immunotherapy in adrenocortical carcinoma : A retrospective cohort study

Author

Remde, Hanna, Schmidt-Pennington, Laura, Reuter, Miriam, Landwehr, Laura-Sophie, Jensen, Marie, Lahner, Harald, Kimpel, Otilia, Altieri, Barbara, Laubner, Katharina, Schreiner, Jochen, Bojunga, Joerg, Kircher, Stefan, Kunze, Catarina Alisa, Pohrt, Anne, Teleanu, Maria-Veronica, Hübschmann, Daniel, Stenzinger, Albrecht, Glimm, Hanno, Fröhling, Stefan, Fassnacht, Martin, Mai, Knut, and Kroiss, Matthias

Subjects
Medizin
Published
2023

13. Nitric Acid Trihydrate (NAT) in Polar Stratospheric Clouds

Author

Voigt, Christiane, Schreiner, Jochen, Kohlmann, Andreas, Zink, Peter, Mauersberger, Konrad, Larsen, Niels, Deshler, Terry, Kröger, Chris, Rosen, Jim, Adriani, Alberto, Cairo, Francesco, Di Donfrancesco, Guido, Viterbini, Maurizio, Ovarlez, Joelle, Ovariez, Henri, David, Christine, and Dörnbrack, Andreas

Published
2000

16. Development of a Pepper Pot Emittance Measurement Device for the HIT-LEBT

Author

Cee, Rainer, Dorn, Christoph, Feldmeier, Eike, Haberer, Thomas, Peters, Andreas, Schreiner, Jochen, and Winkelmann, Tim

Subjects
03 Transverse Profile and Emittance Monitors, Accelerator Physics
Abstract

The Heidelberg Ion Beam Therapy Centre (HIT) is a synchrotron based medical accelerator facility for the treatment of cancer patients with ions. Since the first treatment in November 2009 about 7000 patients have been irradiated with protons or carbon ions and, since July 2021, also with helium ions. In 2010 HIT started the operation of a test bench with a setup comparable to the LEBT at the accelerator. Since 2013 the test bench serves as a common low energy beamline of Siemens Healthcare and HIT with components from both partners. In parallel to ion source and RFQ research and development we have experimented with our proprietary pepper pot device. We plan to install the final version of the pepper pot into the LEBT section and use the measured beam distributions for the design of a new RFQ. With the recent redesign of the mask-target assembly we have increased the active area of the device and generated a possibility for an accurate pixel calibration by a specialised calibration mask. Our tool PePE (Pepper Pot Emittance Evaluation) offers different approaches for the reconstruction of the 4D emittance parameters from the raw image. The evaluation process was validated by a pepper pot image generated from a simulated beam with known properties., Proceedings of the 10th International Beam Instrumentation Conference, IBIC2021, Pohang, Rep. of Korea

Published
2021
Full Text
View/download PDF

18. Interplay between glucocorticoids and tumor-infiltrating lymphocytes on the prognosis of adrenocortical carcinoma

Author

Landwehr, Laura-Sophie, Altieri, Barbara, Schreiner, Jochen, Sbiera, Iuliu, Weigand, Isabel, Kroiss, Matthias, Fassnacht, Martin, and Sbiera, Silviu

Subjects
ddc:610
Abstract

Background Adrenocortical carcinoma (ACC) is a rare endocrine malignancy. Tumor-related glucocorticoid excess is present in similar to 60% of patients and associated with particularly poor prognosis. Results of first clinical trials using immune checkpoint inhibitors were heterogeneous. Here we characterize tumor-infiltrating T lymphocytes (TILs) in ACC in association with glucocorticoids as potential explanation for resistance to immunotherapy. Methods We performed immunofluorescence analysis to visualize tumor-infiltrating T cells (CD3\(^+\)), T helper cells (CD3\(^+\)CD4\(^+\)), cytotoxic T cells (CD3\(^+\)CD8\(^+\)) and regulatory T cells (Tregs; CD3\(^+\)CD4\(^+\)FoxP3\(^+\)) in 146 ACC tissue specimens (107 primary tumors, 16 local recurrences, 23 metastases). Quantitative data of immune cell infiltration were correlated with clinical data (including glucocorticoid excess). Results 86.3% of ACC specimens showed tumor infiltrating T cells (7.7 cells/high power field (HPF)), including T helper (74.0%, 6.7 cells/HPF), cytotoxic T cells (84.3%, 5.7 cells/HPF) and Tregs (49.3%, 0.8 cells/HPF). The number of TILs was associated with better overall survival (HR for death: 0.47, 95% CI 0.25 to 0.87), which was true for CD4\(^+\)- and CD8\(^+\) subpopulations as well. In localized, non-metastatic ACC, the favorable impact of TILs on overall and recurrence-free survival was manifested even independently of ENSAT (European Network for the Study of Adrenal Tumors) stage, resection status and Ki67 index. T helper cells were negatively correlated with glucocorticoid excess (Phi=-0.290, p=0.009). Patients with glucocorticoid excess and low TILs had a particularly poor overall survival (27 vs. 121 months in patients with TILs without glucocorticoid excess). Conclusion Glucocorticoid excess is associated with T cell depletion and unfavorable prognosis. To reactivate the immune system in ACC by checkpoint inhibitors, an inhibition of adrenal steroidogenesis might be pivotal and should be tested in prospective studies.

Published
2020

20. Determination of polar stratospheric cloud particle refractive indices by use of in situ optical measurements and T-matrix calculations

Author

Scarchilli, Claudio, Adriani, Alberto, Cairo, Francesco, Di Donfrancesco, Guido, Buontempo, Carlo, Snels, Marcel, Moriconi, Maria Luisa, Deshler, Terry, Larsen, Niels, Luo, Beiping, Mauersberger, Konrad, Ovarlez, Joelle, Rosen, Jim, and Schreiner, Jochen

Subjects
Optics -- Research, Algorithms -- Research, Algorithms -- Technology application, Light scattering -- Research, Clouds -- Research, Technology application, Algorithm, Astronomy, Physics
Abstract

A new algorithm to infer structural parameters such as refractive index and asphericity of cloud particles has been developed by use of in situ observations taken by a laser backscattersonde and an optical particle counter during balloon stratospheric flights. All three main particles, liquid, ice, and a no-ice solid (NAT, nitric acid trihydrate) of polar stratospheric clouds, were observed during two winter flights performed from Kiruna, Sweden. The technique is based on use of the T-matrix code developed for aspherical particles to calculate the backscattering coefficient and particle depolarizing properties on the basis of size distribution and concentration measurements. The results of the calculations are compared with observations to estimated refractive indices and particle asphericity. The method has also been used in cases when the liquid and solid phases coexist with comparable influence on the optical behavior of the cloud to estimate refractive indices. The main results prove that the index of refraction for NAT particles is in the range of 1.37-1.45 at 532 nm. Such particles would be slightly prolate spheroids. The calculated refractive indices for liquid and ice particles are 1.51-1.55 and 1.31-1.33, respectively. The results for solid particles confirm previous measurements taken in Antarctica during 1992 and obtained by a comparison of lidar and optical particle counter data. OCIS codes. 010.0010, 290.3030, 290.5850, 010.1110, 290.5820.

Published
2005

22. Expression of SOAT1 in Adrenocortical Carcinoma and Response to Mitotane Monotherapy: An ENSAT Multicenter Study

Author

Weigand, Isabel, primary, Altieri, Barbara, additional, Lacombe, Amanda M F, additional, Basile, Vittoria, additional, Kircher, Stefan, additional, Landwehr, Laura-Sophie, additional, Schreiner, Jochen, additional, Zerbini, Maria C N, additional, Ronchi, Cristina L, additional, Megerle, Felix, additional, Berruti, Alfredo, additional, Canu, Letizia, additional, Volante, Marco, additional, Paiva, Isabel, additional, Della Casa, Silvia, additional, Sbiera, Silviu, additional, Fassnacht, Martin, additional, Fragoso, Maria Candida B V, additional, Terzolo, Massimo, additional, and Kroiss, Matthias, additional

Published
2020
Full Text
View/download PDF

24. SUN-211 Active Steroid Hormone Synthesis Renders Adrenocortical Cells Highly Susceptible to Type II Ferroptosis Induction

Author

Weigand, Isabel, primary, Schreiner, Jochen, primary, Roehrig, Florian, primary, Sun, Na, primary, Laura-Sophie, Landwehr, primary, Urlaub, Hanna, primary, Kiseljak-Vassiliades, Katja, primary, Wierman, Margaret E, primary, Angeli, José Pedro Friedmann, primary, Walch, Axel K, primary, Sbiera, Silviu, primary, Fassnacht, Martin, primary, and Kroiss, Matthias, primary

Published
2020
Full Text
View/download PDF

25. Urine steroid metabolomics as a novel diagnostic tool for recurrent adrenocortical carcinoma detection

Author

Chortis, Vasileios, primary, Bancos, Irina, additional, Nijman, Thomas, additional, Gilligan, Lorna C, additional, Taylor, Angela E, additional, Ronchi, Cristina L, additional, O'Reilly, Michael W, additional, Schreiner, Jochen, additional, Asia, Miriam, additional, Riester, Anna, additional, Terzolo, Massimo, additional, Libe, Rosella, additional, Quinkler, Marcus, additional, Canu, Letizia, additional, Paiva, Isabel, additional, Bugalho, Maria J, additional, Kastelan, Darko, additional, Dennedy, M Conall, additional, Sherlock, Mark, additional, Ambroziak, Urszula, additional, Vassiliadi, Dimitra, additional, Bertherat, Jerome, additional, Beuschlein, Felix, additional, Fassnacht, Martin, additional, Deeks, Jonathan J, additional, Biehl, Michael, additional, and Arlt, Wiebke, additional

Published
2019
Full Text
View/download PDF

26. Urine Steroid Metabolomics as a Novel Tool for Detection of Recurrent Adrenocortical Carcinoma

Author

Chortis, Vasileios, primary, Bancos, Irina, additional, Nijman, Thomas, additional, Gilligan, Lorna C, additional, Taylor, Angela E, additional, Ronchi, Cristina L, additional, O’Reilly, Michael W, additional, Schreiner, Jochen, additional, Asia, Miriam, additional, Riester, Anna, additional, Perotti, Paola, additional, Libé, Rosella, additional, Quinkler, Marcus, additional, Canu, Letizia, additional, Paiva, Isabel, additional, Bugalho, Maria J, additional, Kastelan, Darko, additional, Dennedy, M Conall, additional, Sherlock, Mark, additional, Ambroziak, Urszula, additional, Vassiliadi, Dimitra, additional, Bertherat, Jerome, additional, Beuschlein, Felix, additional, Fassnacht, Martin, additional, Deeks, Jonathan J, additional, Biehl, Michael, additional, and Arlt, Wiebke, additional

Published
2019
Full Text
View/download PDF

30. SUN-350 Sterol-O-Acyl Transferase 1 Protein Expression Alone Is Not Sufficient to Predict Response to Mitotane Treatment in Adrenocortical Carcinoma

Author

Weigand, Isabel, primary, Altieri, Barbara, additional, Ferreira, Amanda, additional, Basile, Vittoria, additional, Landwehr, Laura-Sophie, additional, Ronchi, Cristina, additional, Schreiner, Jochen, additional, Megerle, Felix, additional, Berruti, Alfredo, additional, Canu, Letizia, additional, Volante, Marco, additional, Paiva, Isabel, additional, Della Casa, Silvia, additional, Sbiera, Silviu, additional, Fassnacht, Martin, additional, Fragoso, Maria, additional, Terzolo, Massimo, additional, and Kroiss, Matthias, additional

Published
2019
Full Text
View/download PDF

33. Infiltrating Th1/Th17 cells predominate in Hashimoto's Thyroiditis

Author

Gasser, Martin, Almanzar, Giovanni, Schreiner, Jochen, Höfner, Kerstin, Wild, Vanessa, Rosenwald, Andreas, Germer, Christoph-Thomas, Waaga-Gasser, Ana Maria, and Prelog, Martina

Subjects
endocrine system, endocrine system diseases, ddc: 610, 610 Medical sciences, Medicine
Abstract

Introduction: Hashimoto’s thyroiditis (HT) is an autoimmune thyroid disease characterized by lymphocyte infiltration, fibrosis, and parenchymal atrophy of the thyroid gland. However, little is known about the role of infiltrating T-cells in the etiopathogenesis of HT. The aim of the study was[for full text, please go to the a.m. URL], 132. Kongress der Deutschen Gesellschaft für Chirurgie

Published
2015

34. Urine Steroid Metabolomics as a Novel Tool for Detection of Recurrent Adrenocortical Carcinoma

Author

Chortis, Vasileios, Bancos, Irina, Nijman, Thomas, Gilligan, Lorna C, Taylor, Angela E, Ronchi, Cristina L, O’Reilly, Michael W, Schreiner, Jochen, Asia, Miriam, Riester, Anna, Perotti, Paola, Libé, Rosella, Quinkler, Marcus, Canu, Letizia, Paiva, Isabel, Bugalho, Maria J, Kastelan, Darko, Dennedy, M Conall, Sherlock, Mark, Ambroziak, Urszula, Vassiliadi, Dimitra, Bertherat, Jerome, Beuschlein, Felix, Fassnacht, Martin, Deeks, Jonathan J, Biehl, Michael, and Arlt, Wiebke

Published
2020
Full Text
View/download PDF

37. Large nitric acid containing particles above a PSC cloud

Author

Schreiner, Jochen, Weisser, Christoph, Mauersberger, Konrad, Deshler, Terry, Larsen, Niels, Ovarlez, Joelle, Ovarlez, Henri, Adriani, Alberto, Dörnbrack, Andreas, and Fricke, K. H.

Subjects
PSC, Arctic stratospheric cloud
Published
2002

38. In situ mountain‐wave polar stratospheric cloud measurements: Implications for nitric acid trihydrate formation

Author

Voigt, Christiane, primary, Larsen, Niels, additional, Deshler, Terry, additional, Kröger, Chris, additional, Schreiner, Jochen, additional, Mauersberger, Konrad, additional, Luo, Beiping, additional, Adriani, Alberto, additional, Cairo, Francesco, additional, Di Donfrancesco, Guido, additional, Ovarlez, Joelle, additional, Ovarlez, Henri, additional, Dörnbrack, Andreas, additional, Knudsen, Bjørn, additional, and Rosen, Jim, additional

Published
2003
Full Text
View/download PDF

45. Outcome of immunotherapy in adrenocortical carcinoma: a retrospective cohort study.

Author

Remde H, Schmidt-Pennington L, Reuter M, Landwehr LS, Jensen M, Lahner H, Kimpel O, Altieri B, Laubner K, Schreiner J, Bojunga J, Kircher S, Kunze CA, Pohrt A, Teleanu MV, Hübschmann D, Stenzinger A, Glimm H, Fröhling S, Fassnacht M, Mai K, and Kroiss M

Subjects
Humans, Nivolumab therapeutic use, Retrospective Studies, B7-H1 Antigen therapeutic use, Immunotherapy adverse effects, Immunotherapy methods, Carcinoma, Non-Small-Cell Lung drug therapy, Lung Neoplasms drug therapy, Adrenocortical Carcinoma drug therapy, Antineoplastic Agents, Immunological adverse effects, Adrenal Cortex Neoplasms drug therapy
Abstract

Objective: Clinical trials with immune checkpoint inhibitors (ICI) in adrenocortical carcinoma (ACC) have yielded contradictory results. We aimed to evaluate treatment response and safety of ICI in ACC in a real-life setting., Design: Retrospective cohort study of 54 patients with advanced ACC receiving ICI as compassionate use at 6 German reference centres between 2016 and 2022., Methods: Objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS), overall survival (OS), and treatment-related adverse events (TRAE) were assessed., Results: In 52 patients surviving at least 4 weeks after initiation of ICI, ORR was 13.5% (6-26) and DCR was 24% (16-41). PFS was 3.0 months (95% CI, 2.3-3.7). In all patients, median OS was 10.4 months (3.8-17). 17 TRAE occurred in 15 patients, which was associated with a longer PFS of 5.5 (1.9-9.2) vs 2.5 (2.0-3.0) months (HR 0.29, 95% CI, 0.13-0.66, P = 0.001) and OS of 28.2 (9.5-46.8) vs 7.0 (4.1-10.2) months (HR 0.34, 95% CI, 0.12-0.93). Positive tissue staining for programmed cell death ligand 1 (PD-L1) was associated with a longer PFS of 3.2 (2.6-3.8) vs 2.3 (1.6-3.0, P < 0.05) months. Adjusted for concomitant mitotane use, treatment with nivolumab was associated with lower risk of progression (HR 0.36, 0.15-0.90) and death (HR 0.20, 0.06-0.72) compared to pembrolizumab., Conclusions: In the real-life setting, we observe a response comparable to other second-line therapies and an acceptable safety profile in ACC patients receiving different ICI. The relevance of PD-L1 as a marker of response and the potentially more favourable outcome in nivolumab-treated patients require confirmation., (© The Author(s) 2023. Published by Oxford University Press on behalf of European Society of Endocrinology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.)

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results